FindTrial
Sign In

Piracetam

DRUG8 trials

Sponsors

University of Pennsylvania, Beersheva Mental Health Center, UCB Pharma, UCB S.A. - Pharma Sector, Hannover Medical School

Conditions

Acute Ischaemic Middle Cerebral Artery StrokeAnxiety DisordersCocaine-Related DisordersDementiaDepressionDiabetic Peripheral NeuropathyDrug Adherence MarkerMemory Disorders

Phase 1

Piracetam for Treatment of Cocaine Addiction - 3
CompletedNCT00000198
University of PennsylvaniaCocaine-Related Disorders
Start: 1996-10-31End: 1997-10-31Updated: 2015-10-06
Piracetam for Treatment of Cocaine Addiction, Phase II - 4
WithdrawnNCT00000199
University of PennsylvaniaCocaine-Related Disorders
Updated: 2017-03-30

Phase 3

Piracetam for Treatment Tardive Dyskinesia
CompletedNCT00190008
Beersheva Mental Health CenterTardive Dyskinesia
Start: 2003-08-31Target: 40Updated: 2009-11-25
Pharmacovigilance in Gerontopsychiatric Patients
TerminatedNCT02374567
Hannover Medical SchoolAnxiety Disorders, Dementia, Depression +2
Start: 2015-01-31End: 2017-06-28Updated: 2018-02-28

Phase 4

A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
TerminatedNCT01883011
UCB S.A. - Pharma SectorAcute Ischaemic Middle Cerebral Artery Stroke
Start: 1998-08-31End: 2001-07-31Updated: 2013-08-30
Subtherapeutic Dose of Piracetam as a Therapy Adherence Marker
NCT05918341
The Netherlands Cancer InstituteDrug Adherence Marker
Start: 2023-07-03End: 2023-09-30Target: 10Updated: 2023-06-26
The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients
Not yet recruitingNCT06479629
Ain Shams UniversityDiabetic Peripheral Neuropathy
Start: 2025-02-10End: 2025-11-01Target: 60Updated: 2025-01-28

Unknown Phase

Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)
CompletedNCT00567060
UCB PharmaMemory Disorders
Start: 2000-05-31End: 2004-01-31Updated: 2013-12-16